O
ACHN

OrbiMed’s Achillion Pharmaceuticals ACHN Stock Holding History

OrbiMed’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-8,170,973
Closed -$23.5M – 154
2017
Q4 		$23.5M Sell
8,170,973
-4,891,927
-37% -$17.8M 0.3% 74
2017
Q3 		$58.7M Sell
13,062,900
-44,300
-0.3% -$197K 0.56% 53
2017
Q2 		$60.2M Hold
13,107,200
– – 0.63% 49
2017
Q1 		$55.2M Hold
13,107,200
– – 0.63% 48
2016
Q4 		$54.1M Hold
13,107,200
– – 0.69% 47
2016
Q3 		$106M Buy
13,107,200
+1,425,600
+12% +$12.1M 1.21% 28
2016
Q2 		$91.1M Buy
11,681,600
+161,900
+1% +$1.39M 0.95% 37
2016
Q1 		$88.9M Buy
11,519,700
+1,869,800
+19% +$13.7M 0.94% 33
2015
Q4 		$104M Buy
9,649,900
+4,427,400
+85% +$40.2M 0.94% 36
2015
Q3 		$36.1M Buy
+5,222,500
New +$42.5M 0.36% 55
2015
Q2 		– Sell
-158,000
Closed -$1.56M – 155
2015
Q1 		$1.56M Hold
158,000
– – 0.01% 132
2014
Q4 		$1.94M Hold
158,000
– – 0.02% 122
2014
Q3 		$1.58M Buy
+158,000
New +$1.47M 0.02% 125
2013
Q3 		– Sell
-545,000
Closed -$4.46M – 139
2013
Q2 		$4.46M Buy
+545,000
New +$4.16M 0.09% 104

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

OrbiMed's ACHN Position: Q1 2018 in Review

OrbiMed sold out of Achillion Pharmaceuticals (ACHN) in Q1 2018, closing a stake of 8,170,973 shares — an estimated $23.5M sold.

OrbiMed first reported a position in ACHN in Q2 2013 and held it in 14 quarters. The position peaked at $106M in Q3 2016. 127 funds tracked by Wall St. Rank hold ACHN as of Q1 2018.

  • OrbiMed reported no remaining Achillion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • OrbiMed sold 8,170,973 Achillion Pharmaceuticals shares in Q1 2018, an estimated $23.5M.
  • OrbiMed first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • OrbiMed's Achillion Pharmaceuticals position peaked at $106M in Q3 2016.
  • 127 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2018.

Based on OrbiMed's 13F filing for Q1 2018, filed 15 May 2018.